Back to search

Aristotle University Of Thessaloniki (AUTH)

Η επίδραση της κλοπιδογρέλης στη θρομβογένεση κατά τη διάρκεια της διαφλέβιας μέσω καθετήρα κατάλυσης με υψίσυχνο ρεύμα

Abstract

dc:description

Objectives: We sought to investigate the activation of the coagulation system in relation to aspirin and clopidogrel pretreatment during radiofrequency ablation (RFA) procedures. Also, to evaluate the relation of RFA parameters (procedure duration, radiation time, number and duration of RF applications, mean temperature and mean power) to specific indices of coagulation-fibrinolysis. Patients: We studied prospectively 63 patients (29 men, mean age 48 ± 26 years) who underwent RFA for supraventricular tachyarrhythmias in the right heart (atrioventricular nodal re-entry tachycardia n= 41, atrioventricular re-entry tachycardia due to accessory pathway n= 18, isthmus dependent atrial flutter n= 4). Patients were excluded from the study in case of coagulopathy, bleeding disorder or history of antiplatelet/ heparin intake, hepatic or renal failure, recent myocardial wall infarction, peripheral or cerebrovascular disease, congestive heart failure, and history of major operation during the last two months. Methods: Twenty-one patients were randomized in group A and received aspirin (325 mg loading dose, followed by 325 mg per day for one month), twenty-one were randomized in group B and received (300 mg loading dose, followed by 75 mg per day for one month), and twenty-one were randomized in group C and received aspirin (325 mg loading dose, followed by 325 mg per day for one month) and clopidogrel (300 mg loading dose, followed by 75 mg per day for one month). Platelet aggregation (PA) mediated by adenosine diphosphate (ADP) and collagen, activation of coagulation (thrombin-antithrombin complex -TAT), and the fibrinolytic activity (D-dimer, D-d) levels were assessed. Blood samples were collected at baseline -before sheath insertion (T1), on completion of the RFA procedure (T2), 24 hours later (T3) and after 1 month (T4). Results: Two patients were excluded from the study (one due to skin rash developed one week after RFA, which was attributed to clopidogrel, and the other due to cardiac tamponade, developed during RFA, from group C). The analysis concluded 61 patients, in whom RFA was completed successfully. No serious side effects were reported among the patient population. No thromboembolic events were reported in either of the study groups during hospitalization, or during monthly follow-up. ADP-induced aggregation was significantly inhibited in all groups over time (p<0.001 in group A, p<0.001 in group B, and p<0.001 in group C). ADP-induced aggregation was statistically significant in group B compared to A over time (p<0.001), in group C compared to A over time (p<0.001), and in group C compared to B (p<0.001) over time. Collagen-induced aggregation was significantly inhibited in all groups over time (p<0.001 in all groups). ANOVA analysis revealed that collagen-induced aggregation was statistically significant in group B compared to A over time (p<0.001), in group C compared to A over time (p<0.001), and in group C compared to B over time (p<0.001). Within groups median plasma D-d levels increased sixfold (p<0.001) in group A, fivefold (p<0.001) in group B and less than twofold (p<0.001) in group C after RFA was completed. However, 24 hour later, mean plasma D-d concentration was still elevated, but decreased compared to T2 sample in both groups, while declined to baseline values at T4. Within groups, plasma D-d levels showed significant increase from T1 to T4 (p<0.001) in all groups. Statistically significantly lower D-d levels were observed in group B compared to group A over time (p<0.001), in group C compared to A over time (p<0.001), and in group C compared to group B over time (p<0.001). Within groups median plasma TAT levels showed significant elevations over time. TAT concentration increased ninefold (p<0.001) in group A, eightfold (p<0.001) in group B and C. Twenty four hours later, TAT levels remained elevated compared to baseline, but declined compared to T2 and returned to baseline levels in all groups after one month. However, there was no statistically significant difference concerning TAT levels after intergroup comparison over time (p>0.05). In a univariate regression analysis that was performed, no significant correlation between platelet aggregation or coagulation markers and procedural characteristics (number and mean duration of application, mean temperature and mean power, and total procedure duration) was demonstrated. There was only a week positive correlation between TAT and D-d levels (at T2 and T3) and total procedure duration. Conclusions: This prospective clinical study in patients undergoing RFA procedure has demonstrated that the combination of clopidogrel and aspirin significantly inhibits ADP and collagen-induced platelet aggregation and causes significantly less pronounced rise in plasma D-dimer levels, compared to aspirin or clopidogrel alone. However, neither the combination nor clopidogrel or aspirin alone, appears to modulate coagulation cascade, as indicated by thrombin generation. Further studies are warranted to confirm the beneficial effect of clopidogrel on the thrombogenic potential of RFA.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2007

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Polymeropoulos, Konstantinos
  • Πολυμερόπουλος, Κωνσταντίνος

Subjects

dc:subject × 15

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/19583

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Polymeropoulos, Konstantinos; Πολυμερόπουλος, Κωνσταντίνος. Η επίδραση της κλοπιδογρέλης στη θρομβογένεση κατά τη διάρκεια της διαφλέβιας μέσω καθετήρα κατάλυσης με υψίσυχνο ρεύμα. Aristotle University Of Thessaloniki (AUTH), 2007. http://hdl.handle.net/10442/hedi/19583